Comments
Shares of Glenmark Pharmaceuticals on Friday zoomed nearly 8 per cent after the company posed a profit of ₹255.45 crore in the September quarter. The stock zoomed 7.77 per cent to ₹304.25 on the BSE. On the NSE, it rose 7.94 per cent to ₹304.45.
Drug firm Glenmark Pharmaceuticals Ltd on Thursday reported a consolidated net profit to ₹255.54 crore for the second quarter ended on September, 2019.
The company had posted a net profit of ₹414 crore in the July-September quarter a year ago, Glenmark Pharmaceuticals said in a BSE filing.
The net profit is not comparable to the previous corresponding quarter on account of an exceptional income of ₹167.18 crore recorded in the second quarter of the previous financial year, the company said.
Commenting on the results Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said, “We have rebounded strongly in the second quarter with most of our businesses recording good growth. The India business has continued to witness strong growth while the US sales have grown quarter over quarter sequentially. The Latam business has also recovered well in the second quarter.
Net sales of the company stood at ₹2,763.73 crore, up 8.81 per cent, during the period under review as against ₹2,539.85 crore of the corresponding quarter previous fiscal.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.